Reovirus for the treatment of neoplasia
AssigneeOncolytics Biotech Inc.
InventorsPatrick W. K. Lee, James Strong, Matthew C. Coffey
Life of this patent
Estimating the term…
Loading patent…
AssigneeOncolytics Biotech Inc.
InventorsPatrick W. K. Lee, James Strong, Matthew C. Coffey
Estimating the term…
Methods for treating neoplasia, by administering reovirus to a Ras-mediated neoplasm, and use of reovirus for manufacture of a medicament for the treatment of neoplasia, are disclosed. The reovirus is administered so that it ultimately directly contacts cells of the neoplasm. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, type 1 (e.g., strain Lang), type 2 (e.g., strain Jones), type 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.
A method of treating a Ras-mediated neoplasm in a mammal, comprising administering to the neoplasm a reovirus in an amount sufficient to result in reovirus-mediated oncolysis of cells of the neoplasm.
A method of treating a Ras-mediated neoplasm in a human, comprising administering to the neoplasm a reovirus in an amount sufficient to result in reovirus-mediated oncolysis of cells of the neoplasm.
Dependencies are inferred from the claim text.